H.C. Wainwright Reiterates Buy Rating on Praxis Precision Medicines Inc. (PRAX)

April 7, 2026 7:45 AM

H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating and $1,245.00 price target on Praxis Precision Medicines Inc. (NASDAQ: PRAX).The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found